Key information

🔎 Fund Overview

GeoVax Labs, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using its platforms. Its product pipeline includes ongoing human clinical trials for a COVID-19 and a gene-directed therapy against advanced head and neck cancers. It is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations. Its research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg and Lassa) and Zika virus, as well as immunotherapies for multiple solid tumors. Its wholly owned subsidiary is GeoVax, Inc.